Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis

Cell Reports

Volumn 14, Issue 10, 2016, Pages 2337-2347

  Grabow, Stephanie ^a,b   Delbridge, Alex R D ^a,b   Aubrey, Brandon J ^a,b,c   Vandenberg, Cassandra J ^a,b   Strasser, Andreas ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Apoptosis; BIM; Lymphoma; MCL 1; MYC; P53

Indexed keywords

BIM PROTEIN; MYC PROTEIN; PROTEIN MCL 1; PROTEIN P53; PUMA PROTEIN; APOPTOSIS REGULATORY PROTEIN; MCL1 PROTEIN, MOUSE; PUMA PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; LYMPHOMA; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN INTERACTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW; C57BL MOUSE; CYTOLOGY; DNA SEQUENCE; FLOW CYTOMETRY; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; KNOCKOUT MOUSE; METABOLISM; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ALLELES; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-LIKE PROTEIN 11; BONE MARROW; FLOW CYTOMETRY; GENOTYPE; KAPLAN-MEIER ESTIMATE; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PRECURSOR CELLS, B-LYMPHOID; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84960364267     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.02.039     Document Type: Article

References (49)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318:533-538.
2. Bachmann P.S., Piazza R.G., Janes M.E., Wong N.C., Davies C., Mogavero A., Bhadri V.A., Szymanska B., Geninson G., Magistroni V., et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010, 116:3013-3022.
3. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
4. Bouillet P., Metcalf D., Huang D.C.S., Tarlinton D.M., Kay T.W.H., Köntgen F., Adams J.M., Strasser A. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999, 286:1735-1738.
5. Brady C.A., Jiang D., Mello S.S., Johnson T.M., Jarvis L.A., Kozak M.M., Kenzelmann Broz D., Basak S., Park E.J., McLaughlin M.E., et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011, 145:571-583.
6. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., Huang D.C.S. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 2005, 17:393-403.
7. Delbridge A.R., Valente L.J., Strasser A. The role of the apoptotic machinery in tumor suppression. Cold Spring Harb. Perspect. Biol. 2012, 4:a008789.
8. Delbridge A.R., Grabow S., Bouillet P., Adams J.M., Strasser A. Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis. Oncogene 2015, 34:1872-1876.
9. Delbridge A.R., Opferman J.T., Grabow S., Strasser A. Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress. Blood 2015, 125:3273-3280.
10. Egle A., Harris A.W., Bouillet P., Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl. Acad. Sci. USA 2004, 101:6164-6169.
11. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999, 13:2658-2669.
12. Garrison S.P., Jeffers J.R., Yang C., Nilsson J.A., Hall M.A., Rehg J.E., Yue W., Yu J., Zhang L., Onciu M., et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol. Cell. Biol. 2008, 28:5391-5402.
13. Glaser S.P., Lee E.F., Trounson E., Bouillet P., Wei A., Fairlie W.D., Izon D.J., Zuber J., Rappaport A.R., Herold M.J., et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012, 26:120-125.
14. Goodwin C.M., Rossanese O.W., Olejniczak E.T., Fesik S.W. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Differ. 2015, 22:2098-2106.
15. Grabow S., Waring P., Happo L., Cook M., Mason K.D., Kelly P.N., Strasser A. Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice. Cell Death Differ. 2012, 19:623-632.
16. Grabow S., Delbridge A.R., Valente L.J., Strasser A. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood 2014, 124:3939-3946.
17. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
18. Happo L., Cragg M.S., Phipson B., Haga J.M., Jansen E.S., Herold M.J., Dewson G., Michalak E.M., Vandenberg C.J., Smyth G.K., et al. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood 2010, 116:5256-5267.
19. Harris A.W., Pinkert C.A., Crawford M., Langdon W.Y., Brinster R.L., Adams J.M. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 1988, 167:353-371.
20. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994, 4:1-7.
21. Jeffers J.R., Parganas E., Lee Y., Yang C., Wang J., Brennan J., MacLean K.H., Han J., Chittenden T., Ihle J.N., et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003, 4:321-328.
22. Kelly P.N., Puthalakath H., Adams J.M., Strasser A. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Blood 2007, 109:4907-4913.
23. Kelly P.N., Grabow S., Delbridge A.R.D., Strasser A., Adams J.M. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. Blood 2011, 118:6380-6386.
24. Kelly G.L., Grabow S., Glaser S.P., Fitzsimmons L., Aubrey B.J., Okamoto T., Valente L.J., Robati M., Tai L., Fairlie W.D., et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 2014, 28:58-70.
25. Koss B., Morrison J., Perciavalle R.M., Singh H., Rehg J.E., Williams R.T., Opferman J.T. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. Blood 2013, 122:1587-1598.
26. Kuwana T., Bouchier-Hayes L., Chipuk J.E., Bonzon C., Sullivan B.A., Green D.R., Newmeyer D.D. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 2005, 17:525-535.
27. Langdon W.Y., Harris A.W., Cory S., Adams J.M. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 1986, 47:11-18.
28. Lee Y.Y., Moujalled D., Doerflinger M., Gangoda L., Weston R., Rahimi A., de Alboran I., Herold M., Bouillet P., Xu Q., et al. CREB-binding protein (CBP) regulates β-adrenoceptor (β-AR)-mediated apoptosis. Cell Death Differ. 2013, 20:941-952.
29. Leverson J.D., Zhang H., Chen J., Tahir S.K., Phillips D.C., Xue J., Nimmer P., Jin S., Smith M., Xiao Y., et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015, 6:e1590.
30. Li T., Kon N., Jiang L., Tan M., Ludwig T., Zhao Y., Baer R., Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149:1269-1283.
31. Michalak E.M., Jansen E.S., Happo L., Cragg M.S., Tai L., Smyth G.K., Strasser A., Adams J.M., Scott C.L. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ. 2009, 16:684-696.
32. Muthalagu N., Junttila M.R., Wiese K.E., Wolf E., Morton J., Bauer B., Evan G.I., Eilers M., Murphy D.J. BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Rep. 2014, 8:1347-1353.
33. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7:683-694.
34. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
35. Okamoto T., Coultas L., Metcalf D., van Delft M.F., Glaser S.P., Takiguchi M., Strasser A., Bouillet P., Adams J.M., Huang D.C. Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis. Proc. Natl. Acad. Sci. USA 2014, 111:261-266.
36. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
37. Richter-Larrea J.A., Robles E.F., Fresquet V., Beltran E., Rullan A.J., Agirre X., Calasanz M.J., Panizo C., Richter J.A., Hernandez J.M., et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010, 116:2531-2542.
38. Schwenk F., Baron U., Rajewsky K. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 1995, 23:5080-5081.
39. Soucek L., Evan G.I. The ups and downs of Myc biology. Curr. Opin. Genet. Dev. 2010, 20:91-95.
40. Strasser A., Elefanty A.G., Harris A.W., Cory S. Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J. 1996, 15:3823-3834.
41. Tagawa H., Karnan S., Suzuki R., Matsuo K., Zhang X., Ota A., Morishima Y., Nakamura S., Seto M. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005, 24:1348-1358.
42. Valente L.J., Gray D.H., Michalak E.M., Pinon-Hofbauer J., Egle A., Scott C.L., Janic A., Strasser A. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 2013, 3:1339-1345.
43. Valente L.J., Grabow S., Vandenberg C.J., Strasser A., Janic A. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53. Oncogene 2015, Published online December 7, 2015. 10.1038/onc.2015.457.
44. Vikstrom I., Carotta S., Lüthje K., Peperzak V., Jost P.J., Glaser S., Busslinger M., Bouillet P., Strasser A., Nutt S.L., Tarlinton D.M. Mcl-1 is essential for germinal center formation and B cell memory. Science 2010, 330:1095-1099.
45. Villunger A., Michalak E.M., Coultas L., Müllauer F., Böck G., Ausserlechner M.J., Adams J.M., Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003, 302:1036-1038.
46. Vousden K.H., Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8:275-283.
47. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
48. Xiang Z., Luo H., Payton J.E., Cain J., Ley T.J., Opferman J.T., Tomasson M.H. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J. Clin. Invest. 2010, 120:2109-2118.
49. Yu H., Shen H., Yuan Y., XuFeng R., Hu X., Garrison S.P., Zhang L., Yu J., Zambetti G.P., Cheng T. Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-irradiation. Blood 2010, 115:3472-3480.